Loading organizations...
FIGUR8 develops an FDA-registered bioMotion Assessment Platform (bMAP), an advanced system that provides objective, lab-grade biomechanics data for musculoskeletal (MSK) assessments. This platform leverages on-body technology and cloud analytics to capture precise movement data, enabling clinicians to move beyond subjective evaluation methods. The core offering delivers consistent and clear measures for MSK health and injury recovery.
The company originated as an MIT spin-off, founded on the insight that existing musculoskeletal assessment tools were often imprecise and subjective. This realization drove the development of a solution to bring data-driven accuracy and objective measurement to a field previously lacking such rigorous metrics, ultimately aiming to improve diagnostic and treatment pathways.
FIGUR8's platform serves a diverse clientele, including healthcare providers, patients, and payers. It supports providers in creating personalized treatment plans, assists patients in monitoring their recovery, and helps payers enhance claims precision and reduce costs. The company's overarching vision is to fundamentally improve MSK care decisions and outcomes throughout the healthcare system by providing unprecedented visibility into musculoskeletal disorders.
FIGUR8 has raised $42.0M across 3 funding rounds.
FIGUR8 has raised $42.0M in total across 3 funding rounds.
FIGUR8 is a Boston-based medtech company developing the first FDA-registered platform for objective, at-home musculoskeletal (MSK) diagnostics and rehabilitation using lightweight, on-body sensors and AI-driven software.[1][2][3] The bioMotion Assessment Platform (bMAP) serves clinicians, physical therapists, payers, and patients by replacing subjective MSK assessments with precise, real-time biomechanics data, enabling telemedicine, personalized recovery plans, faster claims closure, and better outcomes in injury diagnosis, treatment, and tracking.[1][3][7] Growth momentum includes emergence from stealth mode, third-party research validation, partnerships like the American Physical Therapy Association pledge, and expansions into payer solutions and recovery indicators.[3][4][5][7]
FIGUR8 originated from a unique collaboration between MIT scientists, Massachusetts General Hospital Orthopaedics, and the Boston Red Sox to improve MSK injury diagnosis and treatment.[2] Founded by CEO Nan-Wei Gong, Ph.D., an MIT graduate and serial entrepreneur specializing in biomechanical insights, the company leveraged this expertise to create its novel sensor technology.[2] Early traction came from adapting clinic-based diagnostics for home use, achieving FDA registration, and gaining endorsements from sports and medical institutions, marking pivotal moments in shifting MSK care from subjective to data-driven.[1][2][3]
FIGUR8 rides the wave of digital health transformation, particularly in MSK care—a market strained by subjective diagnostics amid rising telemedicine adoption post-pandemic and wearable tech proliferation.[1][2][3] Timing aligns with demands for quantifiable biomarkers in rehab and workers' comp, where imprecise assessments delay recovery and inflate costs; FIGUR8's sensors address this by enabling home-based, clinician-linked monitoring.[3][7] Favorable forces include AI integration for personalized medicine, payer incentives for cost savings, and research momentum (e.g., third-party validations in *Sensors* and *International Biomechanics*).[4] It influences the ecosystem by setting a new data standard, empowering physical therapists and reducing healthcare burdens through objective movement analysis.[2][3][4]
FIGUR8 is poised for expansion by scaling bMAP into enterprise payer contracts, sports performance, and global telehealth, leveraging its FDA status and real-world data for AI-enhanced features like predictive recovery models.[3][7] Trends in wearable biomechanics, value-based care, and MSK prevalence (from aging populations and remote work injuries) will propel growth, potentially amplifying influence via partnerships with insurers and hospitals.[2][3][6] As the pioneer in accessible MSK sensors, expect broader adoption that redefines precision diagnostics, tying back to its mission of objective insights for healthier movement worldwide.[1][2]
FIGUR8 has raised $42.0M in total across 3 funding rounds.
FIGUR8's investors include Manish Kothari, DigiTx Partners, Christina Jenkins, E14 Fund, P5 Health Ventures, Phoenix Venture Partners, Greylock, Habib Haddad.
FIGUR8 has raised $42.0M across 3 funding rounds. Most recently, it raised $25.0M Series A in August 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 8, 2023 | $25.0M Series A | Manish Kothari | DigiTx Partners, Christina Jenkins |
| Jun 23, 2021 | $12.0M Series A | E14 Fund, P5 Health Ventures, Phoenix Venture Partners | |
| Aug 1, 2019 | $5.0M Seed | P5 Health Ventures | Greylock, Habib Haddad |